What is it about?
The review covers liquid biopsy biomarkers like ctDNA, CTCs, soluble proteins, and exosomes for monitoring cancer treatment responses. ctDNA and CTCs provide insights into tumor characteristics, while soluble proteins and exosomes help predict treatment effectiveness. The review also discusses detection challenges and advanced technologies to improve their use.
Featured Image
Photo by Takashi Miyazaki on Unsplash
Why is it important?
Using blood tests to track how well cancer treatments are working is crucial because they allow doctors to monitor treatment effectiveness, detect changes in the tumor early, and personalize treatments for better results. These tests are less invasive than traditional biopsies, making them safer and easier for patients. Additionally, they help track the tumor's evolution over time, which is essential for long-term treatment planning. These benefits make blood tests a valuable tool in improving cancer care and outcomes
Perspectives
Using blood tests to track cancer treatment responses offers several important perspectives. From the patient's viewpoint, these tests are less invasive and more comfortable than traditional biopsies, reducing stress and discomfort. Clinically, they provide doctors with real-time insights into treatment effectiveness, enabling personalized and timely adjustments. For researchers, blood tests yield valuable data on tumor biology and responses, advancing cancer research and therapy development. From a healthcare system perspective, they can lower costs by reducing the need for invasive procedures and hospital visits, streamlining the monitoring process. Technologically, advancements in blood test methods are enhancing their accuracy and utility, driving innovation in cancer care. These perspectives underscore the multifaceted benefits of blood tests in modern oncology.
Associate Prof. Lifeng Kang
University of Sydney
Read the Original
This page is a summary of: Liquid biopsy for cancer immunotherapy: Biomarkers to predict and monitor response upon immune checkpoint blockade, Coordination Chemistry Reviews, September 2025, Elsevier,
DOI: 10.1016/j.ccr.2025.216767.
You can read the full text:
Resources
Contributors
The following have contributed to this page







